Researching novel therapeutic strategies for neurodegenerative conditions

Usp14 and cellular protein quality control

Usp14 (ubiquitin-specific protease 14) is a member of a family of de-ubiquitinating enzymes that fall within the Proteostasis Network (PN) and act as the cell’s protein quality control system.

Preclinical research has shown that inhibition of Usp14 activates proteasomes, which are tasked with protein destruction, and increases the degradation rate of aggregation-prone proteins. A number of neurodegenerative conditions are associated with high levels of toxic protein aggregates, including Alzheimer’s disease and Parkinson’s disease.

Mediating the cellular stress response

Proteostasis Therapeutics is researching Usp14 inhibition as a means of enhancing clearance of aggregation-prone proteins in a number of diseases, including:

  • α-synuclein in Parkinson’s disease
  • Tau in Alzheimer’s disease

Our goal is to generate novel therapeutic options for patients with conditions for which there are currently no adequate treatment options.

This program is fully owned by Proteostasis Therapeutics, Inc.